STRUCTURE AND FUNCTION STUDIES OF THE HUMAN
DOPAMINE RECEPTORS

Thesis by

M. Yashar S. Kalani
Departments of Chemistry and Biology

In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in

Biochemistry and Molecular Biophysics (Chemistry)

California Institute of Technology

Pasadena, California

2004
This thesis is dedicated to my biological and scientific parents:

Mohammad Kalani, LL.M., and Afrouz Mehrazarin, LL.M.

William A. Goddard, III, Ph.D., Kendall N. Houk, Ph.D., and Vaidehi Nagarajan, Ph.D.
Acknowledgments

I hereby would like to thank all those who have played a part in my development as a member of the society and the scientific community.

First and foremost, I would like to thank my parents and family, whose support and guidance have helped me sail through difficult chapters of my life. My father and mother have been ultra-supportive, and this thesis is dedicated to their efforts and sacrifices. I would also like to thank my grandmothers (here is your first “doctorate grandson”).

I would also like to acknowledge the efforts, guidance, and support of my scientific parents Bill Goddard, Ken Houk, and Vaidehi Nagarajan. All these individuals have had a direct impact on my personal and professional life. Thank you for your support; thank you for teaching me how to do science and how to deal with the politics of science.

Furthermore, I would like to thank my brother, friends, and scientific colleagues who have supported me throughout my academic years. Thank you (in alphabetical order) Peter “Helix-Envy” Freddolino (A.K.A. Adrenaline), Spencer E. Hall (A.K.A. Grandpa), Maziyar A. Kalani, Emile C. Pinera, Caius Radu, Nancy L. Tran, Professor Owen Witte, and Li Yang. Also, thank you members of the MSC who have at one point or another been helpful to me.

I would also like to take this time to thank Mrs. Hallie Fraser (formerly Miss Hallie Lecker), my Taekwondo instructor, mentor, and friend for all of her help and training. Mrs. Fraser was my inspiration and role model during my teenage years and I thank her for the direction and motivation she provided for me.
The next chapter of my life will take me to medical school at Johns Hopkins University School of Medicine where I will pursue my studies towards a Doctor of Medicine degree. Thank you to all who supported me as I prepared for medical school. Most notably, I would like to thank Drs. G. Jennifer Wilson, Robert N. Schwartz, Dominic Thomas, David Cohen (RIP), Steve Hardinger, and Steven G. Clarke.

This thesis is appropriately dedicated to the individuals whose support, love, and dedication have prepared me for a career as a medical scientist: Mom, Dad, Bill, Ken, and Vaidehi.
Abstract

Dopamine neurotransmitter and its receptors play a critical role in cell signaling process responsible for information transfer in neurons functioning in the nervous system. Development of improved therapeutics for such disorders as Parkinson’s and schizophrenia would be significantly enhanced with the availability of the three-dimensional (3-D) structure for the dopamine receptors and of the binding site for dopamine and other agonists and antagonists. In this thesis, I report the 3-D structures of the 5 subtypes of the human dopamine receptors, predicted from primary sequence using first principles theoretical and computational techniques. I use the term “first principles” to mean that we do not use the high resolution crystal structure of rhodopsin as a template, nor do we use homology modeling or threading of any kind to determine the structure. Predicting the binding sites, and the relative binding affinities of endogenous ligands and various pharmaceuticals to the 5 receptors validates the predicted structures. These structures correctly predict the critical residues for binding dopamine and several antagonists, identified by mutation studies and give relative binding affinities that correlate well with experiment. The predicted binding site for dopamine and agonists is located between transmembrane helices (TM) 3, 4, 5, and 6, while the best antagonists bind to a site involving TM helices 2, 3, 4, 6, and 7 with minimal contacts to TM 5. We identify characteristic differences between the binding sites of agonists and antagonists, as well as factors that cause differential binding to the 5 subtypes of the human dopamine receptors.

This thesis consists of five chapters that have, or will shortly result in publications. The first chapter is a brief introduction to the field, the motivation for the project, my scientific contributions, and contribution of others on the team. Chapter two introduces the methods and their successes at reproducing experimentally known results for the human D₂ dopamine receptor; it discusses, in great detail, the active site of pharmaceutical agonists and antagonists to the human D₂ dopamine receptor, and highlights the strengths and shortcomings of homology modeling for membrane bound proteins; this chapter will be submitted for publication to the Journal of Molecular
Chapter three reports the results of a blind study performed in collaboration with Aventis Pharmaceuticals. For this study, we were provided with the two-dimensional structure of 9 antagonists and were asked to predict their binding sites, binding affinities, and to explain the differential binding of the ligands to the human D_3 and D_3 dopamine receptors and the human α1A adrenergic receptor. The results of this study are in preparation for submission to the *Journal of Medicinal Chemistry*. Chapters four and five of the thesis give preliminary results of comparative studies of the agonist and antagonist binding sites of the five subtypes of the human dopamine receptors. Chapter 6 contains results of another blind study on the G2A receptor with Professor Owen Witte.

In addition to the six main chapters, this thesis contains 6 independent appendices that report results of similar studies in other systems. The first 2 appendices are work that has already been published. The remaining 4 appendices will shortly result in publications, but at this time, they are not publication worthy; these appendices represent data that has been analyzed but has not been written in paper format.

In addition, I would like to make note of the studies that I have conducted on the 9 subtypes of the human adrenergic receptors with Mr. Peter Freddolino, the 4 human histamine receptors that were conducted with Mr. Freddolino and Mr. Maziyar Kalani, and the 4 G2A-like lipid receptors conducted with Mr. Rene Trabanino, Dr. Radu, Dr. Yang, and Professor Owen Witte of the Howard Hughes Medical Institute at the David Geffen School of Medicine at the University of California, Los Angeles.
Career Goals and Objectives: I intend to work as a Professor at a large research institution, combining my skills in Physical Chemistry with Biology and Medicine.

Education:

University of California, Los Angeles (1998-2002)

Bachelor in Science (B.S.): Biochemistry

Master in Science (M.S.): Chemistry (Organic Specialization)

Magna Cum Laude; College Honors; Departmental Honors; Chancellor’s Service Award and Departmental Scholar (Chemistry and Biochemistry)

California Institute of Technology (2002-2004)

Master in Science (M.S.): Chemistry (Biochemistry and Molecular Biophysics)

Candidate for the degree of Philosophy Doctorate (Ph.D.): Chemistry (Biochemistry and Molecular Biophysics)

Johns Hopkins University School of Medicine (2004-2008)

Candidate for the degree of Doctorate in Medicine (M.D.) (Class of 2008)
Publications:


References:

Dr. William A. Goddard, III: Department of Chemistry, Caltech, CA.
Dr. K. N. Houk: Department of Chemistry, UCLA, CA.
Dr. Vaidehi Nagarajan: Department of Chemistry, Caltech, CA.
Dr. R.N. Schwartz: Department of Chemistry, UCLA, CA.
Dr. G. Jennifer Wilson: Honors, UCLA, CA.
Dr. Richard Dickerson: Department of Chemistry, UCLA, CA.
Dr. Bruce Rothschild: Department of Mathematics, UCLA, CA.
Dr. Steven Hardinger: Department of Chemistry, UCLA, CA.
Dr. Dominic Thomas: Department of Humanities, UCLA, CA.
Dr. Owen Witte: Howard Hughes Medical Institute, UCLA, CA.
Dr. Steven Clarke: Molecular Biology Institute, UCLA, CA.
# Table of Contents

**Chapter I:** Introduction  .................................................................................................................. 1-12

**Chapter II:** Tertiary Structure and Ligand Binding Sites of the Human D₂ Dopamine Receptor .......................................................................................................................... 13-80

**Chapter III:** First Principles Predictions and Validation of the Binding of Pharmaceutical Antagonists to Human D2 Dopamine Receptor ......................................................... 81-104

**Chapter IV:** A Comparison of the Dopamine Binding Sites of the Human Dopamine Receptors ................................................................................................................................. 105-143

**Chapter V:** A Comparison of the Agonist and Antagonist Binding Sites of the Human Dopamine Receptors ..................................................................................................................... 144-178

**Chapter VI:** The Structure and Function of the Human G₂A Receptor: Collaboration Between Theory and Experiment ................................................................. 179-210

**Appendix I:** The Predicted Three-Dimensional Structure of the Human D₂ Dopamine Receptor and the Binding Site and Binding Affinities for Agonists and Antagonists (Published in the Proceedings of the National Academy of Sciences, U.S.A., 2004) .................................................................................................................. 211-217

**Appendix II:** Predicted 3-D Structure for Human β₂ Adrenergic Receptor and the Binding Site for Agonists and Antagonists (Published in the Proceedings of the National Academy of Sciences, U.S.A., 2004) .................................................................................................................. 218-224

**Appendix III:** The Predicted Structure of the Human D₁ Dopamine Receptor ................................. 225-251

**Appendix IV:** The Predicted Structure of the Human D₃ Dopamine Receptor ................................. 252-276

**Appendix V:** The Predicted Structure of the Human D₄ Dopamine Receptor ................................. 277-301

**Appendix VI:** The Predicted Structure of the Human D₅ Dopamine Receptor ................................. 302-328
**List of Illustrations and Tables**

**Figure 2-1.** Structure for human D₂ dopamine receptor predicted using MembStruk (green) overlaid upon the 2.8-Å crystal structure of BovRhod (blue). ..........................55

**Table 2-1.** Important structural parameters of the human dopamine receptor. ..............56

**Table 2-2.** The binding energy (kcal/mol) relative to dopamine of the ligands used in this study. Based on the criteria of one hydrogen bond to the sequence of TM5 serines for antagonism and two hydrogen bonds for agonism, we have correctly classified the ligands as agonists or antagonists. Sulpiride is the only antagonist which has interactions with both Ser193 and Ser197 but is an antagonist; this observation suggests that not only number but also strengths of the hydrogen bonds are important factors. ..................57

**Figure 2-2a-g.** A helix-by-helix analysis of the hD2DR (MS). Charged residues (blue), aromatics (purple), and polar (red) residues are highlighted. The right side of each helix is in contact with the ligand, while the right hand side is facing the water accessible crevice. The third transmembrane helix is not in direct contact with the lipid and is not color-coded according the other helices in direct contact with the lipid bilayer. SCAM studies (as reviewed by Shi and Javitch (reference 18)) identify the presence of the following residues in each helix in the water accessible crevice: **H1:** G51, N52, A58, and V59; **H2:** D80, L81, V83, V87, W90, and V91; **H3:** D108, I109, F110, V111, V115, C118, S121, I122, L125, and S129; **H4:** W160, P160, and L171; **H5:** P201, S193, S197; **H6:** 1377, V378, W386, F389, F390, T392, H393, I394, and I397; **H7:** L407, F411, T412, W413, Y416, N418, N422, P423. ..............................................................58-59

**Figure 2-3.** This figure shows the predicted structure hD2DR (MS), overlaid with all residues identified experimentally as solvent-accessible (and thus interior to the helical bundle) highlighted in yellow. For all helices except TM4, our predicted structure has
TM positions and rotations that correspond very well with experiment. Indeed for TM4 the solvent accessibility study led to discrepancies the experimental orientation of TM4 in rhodopsin, indicating possible experimental difficulties.

**Figure 2-4.** The two-dimensional figures of 11 agonists and antagonists used in this study.

**Figure 2-5.** The predicted binding site of dopamine, the endogenous ligand of the dopamine receptors. We find that the binding site is located between TM3, 4, 5, and 6.

**Figure 2-6.** The predicted binding site of 7-OH DPAT to the receptor; again the binding site is located between TM3, 5, and 6 with minor contacts to TM4 and 7.

**Figure 2-7.** The predicted binding site of apomorphine to the receptor.

**Figure 2-8.** The predicted binding site of bromocriptine to the receptor.

**Figure 2-9.** The predicted binding site of clozapine to the receptor. We classify clozapine as a class I antagonist, since it binds in the agonist binding site located between TM3, 4, 5, and 6.

**Figure 2-10.** The predicted binding site of haloperidol to the receptor, which we classify as a class II antagonists. This binding site is located between TM2, 3, 4, 5, 6, and 7, quite different from that of class I antagonists (TM3, 4, 5, 6).
Figure 2-11. The predicted binding site of domperidone to the receptor. ---------------68

Figure 2-12. The predicted binding site of raclopride to the receptor. ---------------69

Figure 2-13. The predicted binding site of spiperone to the receptor. ---------------70

Figure 2-14. The predicted binding site of sulpiride to the receptor. ---------------71

Figure 2-15. The predicted binding site of YM-09151-2 to the receptor. -------------72

Figure 2-16. The predicted agonist (dopamine) binding site of the receptor. --------73

Figure 2-17. The predicted class I antagonist (clozapine-like) binding site of the receptor.
----------------------------------------------------------------------------------------------------------------------------------74

Figure 2-18. The predicted class II antagonist (haloperidol-like) binding site of the receptor. -----------------------------------------------75

Figure 2-19. Side by side comparison of scanning results for D2DR Membstruk (A) and homology model (B). Sites are color-coded based on the energy ranges obtained during scanning for ligands in them (-100 – 100=green, 0 - 350=yellow, 200 - 500=orange, 100-900=red). The best identified site for dopamine in each case is colored cyan, and falls into the ‘green’ energy range. Note that in the Membstruk model a cavity within the bundle is predicted as the dopamine-binding site, but this same site in the homology model is quite unfavorable. Proteins are displayed extracellular side up, with helix I on the far left. ----------------------------------------------------------------76
Table 2-3. The change in relative binding energies for several alanine mutants for dopamine relative to the wild type binding energies. -----------------------------------------77

Table 2-4. The change in relative binding energies of several alanine mutants for haloperidol relative to the wild type binding energies. --------------------------------------78

Table 2-5. The binding energy of 10 pharmaceutical ligands to the D2 DR(Vriend) homology model. The more negative the binding energy the better binder is the ligand. Plus signs (+) in the brackets correspond to the following legend: ++++, Inhibition constant (Ki) <0.5 nM; +++, 0.5 nM < Ki < 2- 5 nM; ++, 5 nM < Ki < 50 nM; +, 50 nM < Ki < 500 nM; +/-, 500 nM < Ki < 5 mM; 7-OH-DPAT, 7- hydroxy-dipropylaminotetralin; ND, Not Determined. Data from Missale et al., 1998. ----------------------------------------79

Scheme 2-1. The predicted transmembrane regions of the human D2 dopamine receptor. Residues in red correspond to the transmembrane helices, while the residues in black represent the N & C termini, and the loops connecting the transmembrane domains. ---------------------------------------------------------------------------------------------------------80

Figure 3-1: The nine proprietary Aventis compounds. ----------------------------------------98

Figure 3-2: The predicted binding site for compound 8 (the best binder) to hD2DR. ---------------------------------------------------------------------------------------------------------99

Figure 3-3: A plot of the calculated binding energy versus the experimentally determined inhibition constant for the 9 proprietary Aventis compounds. -------------------------------100
Figure 3-4: The predicted binding site for compound 7 (a good binder) to hD₂DR.

Figure 3-5: The predicted binding site for compound 6 (a medium binder) to hD₂DR.

Figure 3-6: The predicted binding site for compound 3 (a poor binder) to hD₂DR.

Table 3-1: The calculated binding energy of the 9 proprietary Aventis compounds and comparison to the experimentally determined inhibition constants (Ki).

Scheme 4-1. The predicted transmembrane regions of the human D₂ dopamine receptor. Residues in red correspond to the transmembrane helices, while the residues in black represent the N & C termini, and the loops connecting the transmembrane domains.

Scheme 4-2. An analysis of differences in the sequences of human D₂ and D₃ dopamine receptors in the transmembrane domains and the second extracellular loop.

Figure 4-1. The structure of dopamine, a catecholamine neurotransmitter.

Figure 4-2. The scanning results for D₂DR. Sites are color-coded based on the energy ranges obtained during scanning for ligands in them (-100 – 100=green, 0 - 350=yellow, 200 - 500=orange, 100-900=red). The best identified site for dopamine is colored cyan, and falls into the ‘green’ energy range. The protein is displayed extracellular side up, with helix I on the far left.
**Figure 4-3.** The dopamine binding site in the human D₁ dopamine receptor. Details of the salt bridge and hydrogen bonding patterns are shown along with distances. ---------------137

**Figure 4-4.** The dopamine binding site in the human D₂ dopamine receptor. Details of the salt bridge and hydrogen bonding patterns are shown along with distances. ---------------138

**Figure 4-5.** The dopamine binding site in the human D₃ dopamine receptor. Details of the salt bridge and hydrogen bonding patterns are shown along with distances. ---------------139

**Figure 4-6.** The dopamine binding site in the human D₄ dopamine receptor. Details of the salt bridge and hydrogen bonding patterns are shown along with distances. ---------------140

**Figure 4-7.** The dopamine binding site in the human D₅ dopamine receptor. Details of the salt bridge and hydrogen bonding patterns are shown along with distances. ---------------141

**Figure 5-1.** The structure of haloperidol and clozapine, two antagonists of the human dopamine receptors. ----------------------------------------------167

**Figure 5-2.** An overlay of the class I antagonist binding site of clozapine to the D₁ and the D₂ subtypes of the human dopamine receptors. Residues are numbered according to the Ballesteros and Weinstein indexing nomenclature, where the first number represents the transmembrane helix to which the residue belongs to, and the two digit number corresponds to the residue position with respect to the most conserved residue in each helix. Positions 3.28, 3.31, 4.54, 5.37, 5.38, 5.41, 6.55, 6.56, 7.39 and 7.43 in the Clozapine binding site are variable between the D₁-like and D₂-like receptors. The combination of these modifications causes differential binding of ligands to these two families of dopamine receptors. ----------------------------------------------168

**Figure 5-3.** An overlay of the class I antagonist binding site of clozapine to the D₁ and the D₅ subtypes of the human dopamine receptors. Notice that there are no differences in the transmembrane helices that make up the binding sites of these subtypes. Both
receptors have similar binding affinities for ligands. Minor differences in binding affinity may be caused by the second extracellular loop.

**Figure 5-4.** An overlay of the class I antagonist binding site of clozapine to the D₂ versus the D₃ subtypes of the human dopamine receptors. Notice that there are no differences in the transmembrane helices that make up the binding sites of these subtypes. Differences in binding affinity may be caused by the second extracellular loop.

**Figure 5-5.** An overlay of the class I antagonist binding site of clozapine to the D₂ versus the D₄ subtypes of the human dopamine receptors. Positions 2.60, 3.28, 3.31, 3.35, 4.54, 4.58, and 5.38 are variable regions between the D₂ and D₄ proteins.

**Figure 5-6.** An overlay of the class II antagonist-binding site of haloperidol to the D₁-like versus the D₂-like subtypes of the human dopamine receptors. Haloperidol and other class II antagonists have a low affinity for the D₁-like subtypes of the human dopamine receptors due to the presence of a Phe residue at position 3.31 that blocks access to the cavity between TM2 and 7.

**Figure 5-7.** An overlay of the class II antagonist-binding site of haloperidol to the D₁ and the D₅ subtypes of the human dopamine receptors. Notice that there are no differences in the transmembrane helices that make up the binding sites of these subtypes. Both receptors have similar binding affinities for ligands. Minor differences in binding affinity may be caused by the second extracellular loop. The presence of a Phe residue at the 3.31 position blocks the cavity between TM2 and 7 causing class II antagonists to have a low affinity for the D₁ and D₅ receptors.

**Figure 5-8.** An overlay of the class II antagonist-binding sites of haloperidol to the D₂ and D₁ binding sites to the human dopamine receptors. Notice that there are no differences in the transmembrane helices that make up the binding sites of these subtypes. Differences in binding affinity may be caused by the second extracellular loop.
Figure 5-9. An overlay of the class II antagonist binding sites of haloperidol to the D₂ and the D₄ subtypes of the human dopamine receptors. Major differences between the two subtypes are present in the TM2 and TM7 boundary where position 2.60 in the D₂ receptor has been mutated from an aromatic residue to aliphatic residue increasing cavity size in the D₄ receptor. 

Scheme 5-1. The predicted transmembrane regions of the human D₂ dopamine receptor. Residues in red correspond to the transmembrane helices, while the residues in black represent the N & C termini, and the loops connecting the transmembrane domains.

Table 6-1. Multiple cellular effects induced by G2A overexpression.

Figure 6-1. Autoimmunity in G2A⁻/⁻ mice (A) Enlargement of lymphoid organs in G2A⁻/⁻ mice; (B) presence in G2A⁻/⁻ mice of serum autoantibodies reacting against nuclear antigens.

Figure 6-2. Time dependence of [³H] LPC binding to cell homogenates from HEK 293 EGFP (control) or HEK 293 G2A-EGFP (G2A) cells.

Figure 6-3. G2A dependent responses to LPC: (A) transient increases in intracellular calcium concentration in G2A-expressing MCF10A cells; (B) Ga₃-dependent activation of ERK MAP kinase in G2A-expressing CHO cells.

Figure 6-4. Silencing of G2A in DO11.10 cells. (A) The bi-directional human H1-RNA promoter (H1) coordinates expression of the short hairpin RNA (shRNA, RNA pol III dependent) and of EGFP (RNA pol II dependent). Reverse transcription (RT) results in the duplication of the shRNA cassette inserted in the 3’ self inactivating LTR (3’ SIN LTR); (T)₅ – termination signal for the RNA pol III; pA-polyadenylation signal. (B) Expression of the EGFP co-linked marker by retrovirally transduced DO11.10 cells. (C) Expression levels of G2A in DO11.10 T cells transduced with G2A specific (G2A<sub>shRNA</sub>)
or control (CTR\textsuperscript{shRNA}) encoding retroviruses (Western Blot using the rabbit polyclonal antibodies against G2A; ERK2 blot indicates equivalent total protein amounts).

**Figure 6-5.** LPC is a chemotactic factor for DO11.10 cells and this effect is dependent on G2A levels. 2x10\textsuperscript{5} WT and G2A\textsuperscript{shRNA} or control (CTR\textsuperscript{shRNA}, corresponding to a target sequence specific for human TDAG8) cells were washed 3 times with serum-free medium containing 0.1% fatty acid free BSA, mixed and added to the upper chamber of a 24 well plate with 5.0 mm pore size polycarbonate membranes (Costar); LPC (A) or SDF1-a (B) were added to the lower chamber and the plate was incubated for 2 hr at 37\degree C in a 8% CO\textsubscript{2} incubator; (C) Western Blot to estimate the amount of G2A in cells overexpressing the receptor (G2A\textsuperscript{HIGH}). Lysates from G2A\textsuperscript{HIGH} cells were diluted 10 (*) and 20 (**) fold before loading on SDS-PAGE; (D) Transmigration of WT and G2A\textsuperscript{HIGH} cells to LPC.

**Figure 6-6.** Flow chart of MembStruk, the ab initio method for predicting GPCR structures.

**Figure 6-7.** Predicted binding site of LPC in mouse G2A receptor. Residues in transmembrane domains 3, 5, and 6 are involved in binding.

**Figure 6-8.** A: Residues within 5 \AA{} of the choline group of LPC in G2A receptor. B: residues within 5 \AA{} of the phosphate group of LPC; C: Residues within 5 \AA{} of the hydrophobic tail of LPC.

**Figure 6-9.** (A) LPC-induced migration of J774 macrophages infected with G2A mutants. J774A.1 cells were transduced with retroviruses encoding wild type or mutated G2A and functional consequences of the mutations were assessed by examining cell migration towards LPC. The DRY motif and R201 were found to be critical for LPC-induced J774A.1 migration. WT: wildtype G2A; DRY: DRY motif mutation; N11Q:
glycosylation site mutation; L200S and R201A: mutations of predicted LPC binding sites. (B) Western blot using the rabbit polyclonal serum agonist G2A. ------------------203